单位：[1]Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd., Haidian District, Beijing 100142, China[2]Department of General Surgery, China-Japan Friendship Hospital, 100029, China[3]Genecast Biotechnology Co., Beijing 100191, China[4]School of Life Sciences, Tsinghua University, Beijing 100084, China[5]Peking-Tsinghua Center for Life Sciences, China[6]Peking University S.G. Hospital, China
Distant metastasis has been the major concern of prognosis in patients with locally advanced rectal cancer (LARC). The purpose of this study was to investigate the prognostic value of TMB in blood (bTMB) in LARC patients after receiving neoadjuvant chemoradiotherapy (nCRT) and surgery. Using targeted ctDNA sequencing, we revealed that bTMB level at baseline was positively correlated with recurrence-free survival (RFS). Following nCRT, the patients with decreasing TMB tends to have a longer median RFS. bTMB level after surgery was negatively correlated with RFS. The serum cytokines including IFN gamma, IFN alpha 2, IL-1 beta, IL-2 and MIP-1 beta were significantly higher in pre-nCRT serum with higher bTMB group than that of lower bTMB group. Clonal evolution analysis showed that the pre- and post-nCRT ctDNAs of most cases had shared mutations. In conclusion, we presume that bTMB could potentially improve preand post-treatment risk assessment and facilitate individualized therapy for patients with LARC.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772565, 81372593, 81201965]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7132052]; National High Technology Research and Development Program of China (863 Program)National High Technology Research and Development Program of China [2012AA02A506, 2014AA020801]
第一作者单位：[1]Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd., Haidian District, Beijing 100142, China
共同第一作者：
通讯作者：
通讯机构：[1]Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd., Haidian District, Beijing 100142, China[5]Peking-Tsinghua Center for Life Sciences, China[6]Peking University S.G. Hospital, China
推荐引用方式(GB/T 7714)：
Ji Dengbo,Zhang Dakui,Zhan Tiancheng,et al.Tumor mutation burden in blood predicts benefit from neoadjuvant chemo/radiotherapy in locally advanced rectal cancer[J].GENOMICS.2021,113(1):957-966.doi:10.1016/j.ygeno.2020.10.029.
APA：
Ji, Dengbo,Zhang, Dakui,Zhan, Tiancheng,Jia, Jinying,Han, Wenbo...&Gu, Jin.(2021).Tumor mutation burden in blood predicts benefit from neoadjuvant chemo/radiotherapy in locally advanced rectal cancer.GENOMICS,113,(1)
MLA：
Ji, Dengbo,et al."Tumor mutation burden in blood predicts benefit from neoadjuvant chemo/radiotherapy in locally advanced rectal cancer".GENOMICS 113..1(2021):957-966
